BBYBuy
Best Buy
Price (1y)
Fair price check
6 different valuation methods each estimate what BBY should be worth, then we compare to today's price.
- EV/EBITDAUndervaluedthinks it's a bargain — estimates $141.18, about 151% above today
- P/B multiplesUndervaluedthinks it's a bargain — estimates $85.16, about 51% above today
- DCF (2-stage)Undervaluedthinks it's a bargain — estimates $80.46, about 43% above today
- Graham (defensive)Overvaluedthinks it's expensive — estimates $34.06, about 39% below today
- Residual IncomeOvervaluedthinks it's expensive — estimates $30.42, about 46% below today
- P/E multiplesOutlierestimate looks unreliable — estimates $414.20 — likely unreliable
How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.
Fair price ensemble
| Method | Value |
|---|---|
| Graham (defensive) | $34.06 |
| P/E multiples(vs sector peers) | $414.20 |
| P/B multiples(vs sector peers) | $85.16 |
| EV/EBITDA(vs sector peers) | $141.18 |
| Residual Income | $30.42 |
| DCF (2-stage) | $80.46 |
- extreme multiples pe estimate
Median of all applicable methods (current price $56.28). Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.
Pillar breakdown
8 dimensions, each scored 0–100 against the universe
- QualityProfit margins & asset efficiency86Strong
- ValuePrice vs fundamentals91Strong
- GrowthRevenue & earnings trajectory44Weak
- MomentumRecent price strength27Poor
- HealthBalance sheet & solvency45Weak
- ProfitabilityROE, ROA, ROIC57Decent
- TechnicalTrend & volatility signals34Weak
- RiskVolatility & drawdown profile25Poor
Pillars not shown: Sentiment, ML (Phase 5+).
Raw fundamentals (SEC EDGAR)
| Metric | Value |
|---|---|
| Market cap | $11.77B |
| Revenue (TTM) | $46.27B |
| Net income (TTM) | $4.02B |
| Operating cash flow (TTM) | $3.60B |
| CapEx (TTM) | $704.00M |
| Free cash flow (TTM)CFO − CapEx | $2.89B |
| Total assets | $14.67B |
| Total liabilities | N/A |
| Stockholders' equity | $2.96B |
| Cash & equivalents | $1.74B |
| Shares outstanding | 209.11M |
| EPS (basic) | $5.06 |
| EPS (diluted) | $5.04 |
| P/E ratio (TTM) | 2.93 |
TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).
Data quality
- Latest filed date
- 2026-03-18
- Latest period end
- 2026-03-16
- Filing lag
- 59 days
- Missing metrics
- 3(total_liabilities, research_and_development, accounts_receivable)
Phase 3c — composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars land in Phases 5-6; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.